Caribou Biosciences Reports Positive ANTLER Phase 1 Results

Caribou Biosciences ( (CRBU) ) has provided an update.

On November 3, 2025, Caribou Biosciences announced positive results from its ANTLER phase 1 trial, demonstrating that its allogeneic CAR-T cell therapy, vispacabtagene regedleucel (vispa-cel), shows efficacy and durability comparable to autologous CAR-T therapies in treating relapsed or refractory B cell non-Hodgkin lymphoma. The trial results highlight vispa-cel’s potential as a best-in-class therapy due to its off-the-shelf availability and favorable safety profile, which allows for outpatient administration. Additionally, the company shared data from its CaMMouflage phase 1 trial for CB-011, targeting multiple myeloma, and announced plans for a phase 3 trial for vispa-cel in large B cell lymphoma patients ineligible for transplant.

The most recent analyst rating on (CRBU) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Caribou Biosciences stock, see the CRBU Stock Forecast page.

Spark’s Take on CRBU Stock

According to Spark, TipRanks’ AI Analyst, CRBU is a Neutral.

Caribou Biosciences’ overall stock score is primarily impacted by its financial performance challenges, including declining revenues and persistent losses. However, the technical analysis shows positive momentum, which provides some support to the stock. The valuation remains unattractive due to negative earnings and lack of dividends.

To see Spark’s full report on CRBU stock, click here.

More about Caribou Biosciences

Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on CRISPR genome-editing technology. The company specializes in developing allogeneic CAR-T cell therapies for treating various types of cancer, including B cell non-Hodgkin lymphoma and multiple myeloma.

Average Trading Volume: 1,018,442

Technical Sentiment Signal: Buy

Current Market Cap: $225.4M

For an in-depth examination of CRBU stock, go to TipRanks’ Overview page.